EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Effect of Methylphenidate on Cognition in Patients with Comorbid Attention Deficit/Hyperactivity Disorder and Amphetamine Use Disorder: An Exploratory Single-Blinded within-Subject Study

Christoffer Brynte, Maija Konstenius, Lotfi Khemiri, Amanda Bäcker, Joar Guterstam, Frances R Levin, Nitya Jayaram-Lindström, Johan Franck

European Addiction Research · 2024 · 30 (1) · 1-13

DOI: 10.1159/000535016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Addiction Research, online erschienen am 29.11.2023. Verfasst von Christoffer Brynte und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm Health Care Services, Stockholm County Counc…. Hauptthemen laut MEDLINE: Methylphenidate, Attention Deficit Disorder with Hyperactivity, Central Nervous System Stimulants, Substance-Related Disorders. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Attention deficit/hyperactivity disorder (ADHD) with co-occurring substance use disorder (SUD) is associated with poor treatment outcomes. Two randomized controlled trials, utilizing robust doses of stimulants, demonstrated a significant effect on treatment outcomes in patients with ADHD/SUD. This study aimed to investigate differences in executive functioning and explore the dose-dependent effect of OROS-methylphenidate (MPH) in patients with comorbid ADHD and amphetamine use disorder (ADHD+AMPH) and patients with ADHD only.

Methods

Three groups (ADHD+AMPH, ADHD only, and healthy controls) were assessed repeatedly with a neuropsychological test battery. An exploratory within-subject single-blinded design was employed where the ADHD only group received a maximum dose of 72 mg OROS-MPH, the ADHD+AMPH group a maximum dose of 180 mg, whereas the healthy subjects did not receive any study medication. Both ADHD groups received the same dose titration up to 72 mg OROS-MPH.

Results

The ADHD+AMPH group demonstrated a significantly poorer motor inhibition and spatial working memory and reported more severe ADHD symptoms compared to the ADHD only group. 180 mg OROS-MPH was associated with a significant improvement in executive functioning in the dual diagnosis group. However, the exploratory study design and recruitment issues do not allow for any conclusion to be drawn regarding the effect of 180 mg OROS-MPH.

Conclusion

Patients with ADHD+AMPH present with more severe neurocognitive deficits compared to ADHD only. The effect of 180 mg OROS-MPH on cognition in patients with ADHD+AMPH was inconclusive. Future studies should consider recruitment issues and high drop-out rates in this study population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethylphenidateAttention Deficit Disorder with HyperactivityCentral Nervous System StimulantsSubstance-Related DisordersHumansCognitionTreatment OutcomeAmphetaminesDelayed-Action PreparationsRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Amphetamine use disorderAttention deficit/hyperactive disorderDual diagnosis

Substanzen

MethylphenidateCentral Nervous System StimulantsAmphetaminesDelayed-Action Preparations

Autor:innen und Institutionen

  • Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm Health Care Services, Stockholm County Council, Stockholm, Sweden.
  • Department of Psychiatry, Columbia University Irving Medical Center/New York State Psychiatric Institute, New York, New York, USA.

Zitieren

APA

Brynte, C., Konstenius, M., Khemiri, L., Bäcker, A., Guterstam, J., Levin, F. R., Jayaram-Lindström, N., & Franck, J. (2024). The Effect of Methylphenidate on Cognition in Patients with Comorbid Attention Deficit/Hyperactivity Disorder and Amphetamine Use Disorder: An Exploratory Single-Blinded within-Subject Study. European Addiction Research, 30(1), 1-13. https://doi.org/10.1159/000535016

Vancouver

Brynte C, Konstenius M, Khemiri L, Bäcker A, Guterstam J, Levin FR, et al. The Effect of Methylphenidate on Cognition in Patients with Comorbid Attention Deficit/Hyperactivity Disorder and Amphetamine Use Disorder: An Exploratory Single-Blinded within-Subject Study. European Addiction Research. 2024;30(1):1-13. doi:10.1159/000535016

BibTeX
@article{Brynte2024,
  author = {Brynte, Christoffer and Konstenius, Maija and Khemiri, Lotfi and Bäcker, Amanda and Guterstam, Joar and Levin, Frances R and Jayaram-Lindström, Nitya and Franck, Johan},
  title = {The Effect of Methylphenidate on Cognition in Patients with Comorbid Attention Deficit/Hyperactivity Disorder and Amphetamine Use Disorder: An Exploratory Single-Blinded within-Subject Study},
  journal = {European Addiction Research},
  year = {2024},
  volume = {30},
  number = {1},
  pages = {1--13},
  doi = {10.1159/000535016}
}
Kostenlos starten →